Changes in 18F-fluorothymidine and 18F- fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy

Annals of Nuclear Medicine

Volumn 27, Issue 4, 2013, Pages 363-370

  Hoshikawa, Hiroshi ^a   Mori, Terushige ^a   Kishino, Takehito ^a   Yamamoto, Yuka ^a   Inamoto, Ryuhei ^a   Akiyama, Kosuke ^a   Mori, Nozomu ^a   Nishiyama, Yoshihiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Chemoradiation; Early prediction; FDG PET; FLT PET; SUVs

Indexed keywords

3' FLUOROTHYMIDINE F 18; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NEDAPLATIN;

ARTICLE; CANCER PATIENT; CELL DIFFERENTIATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TREATMENT RESPONSE;

EID: 84879096348     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0694-8     Document Type: Article

References (30)

1. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-8.
2. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
3. Sassler AM, Esclamado RM, Wolf GT. Surgery after organ preservation therapy. Analysis of wound complications. Arch Otolaryngol Head Neck Surg. 1995;121:162-5.
4. Nam SY, Lee SW, Im KC, Kim JS, Kim SY, Choi SH, et al. Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET. Oral Oncol. 2005;41:390-5.
5. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10-8.
6. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19:1347-57.
7. Kikuchi M, Nakamoto Y, Shinohara S, Fujiwara K, Yamazaki H, Kanazawa Y, et al. Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. Int J Clin Oncol 2012; 9 [Epub ahead of print].
8. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008;59:203-10.
9. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011;17:3304-15.
10. Greven KM, Williams DW III, Frederick McGuirt SrW, Harkness BA, D'Agostino RB Jr, Keyes JW Jr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942-6.
11. Conessa C, Hervé S, Foehrenbach H, Poncet JL. FDG-PET scan in local follow-up of irradiated head and neck squamous cell carcinomas. Ann Otol Rhinol Laryngol. 2004;113:628-35.
12. Koike I, Ohmura M, Hata M, Takahashi N, Oka T, Ogino I, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys. 2003;57:1231-8.
13. Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med. 1984;25:759-64.
14. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-7.
15. van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
16. Lee TS, Ahn SH, Moon BS, Chun KS, Kang JH, Cheon GJ, et al. Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol. 2009;36:681-6.
17. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-7.
18. Sobin LH, Wittecind C. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
19. Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med. 2009;39:210-32.
20. Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG pet studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-35.
21. Ceulemans G, Voordeckers M, Farrag A, Verdries D, Storme G, Everaert H. Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? Int J Radiat Oncol Biol Phys. 2011;81:938-42.
22. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775-82.
23. Yue J, Chen L, Cabrera AR, Sun X, Zhao S, Zheng F, et al. Measuring tumor cell proliferation with18f-flt pet during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51:528-34.
24. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-47.
25. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause B-J, Fend F, et al. Early response assessment using 3′-deoxy-3′-[18F] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-8.
26. Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-21.
27. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma. 2007;48:746-53.
28. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50:1028-35.
29. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866-74.
30. Hoshikawa H, Nishiyama Y, Kishino T, Yamamoto Y, Haba R, Mori N. Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol Imaging Biol. 2011;13:172-7.